Article

Figures for Interest Grows in Treatment of Mood Disorders by Classic Psychedelics

Author(s):

Nicole Ledwos, MSc,M. Ishrat Husain, MD (Res), MBBS, MRCPsych

This is the extra table for "Interest Grows in Treatment of Mood Disorders by Classic Psychedelics."

Table. Registered Clinical Trials on ClinicalTrials.gov

Table. Registered Clinical Trials on ClinicalTrials.gov

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Subscribe Now!
Related Videos
ketamine
drugs
glutamate
40 years
Tasphong/AdobeStock
Andrii Yalaanskyi/AdobeStock
Jorm Sangsorn/AdobeStock
RolfImages/AdobeStock
CravenA/AdobeStock
Related Content
kidney urinary analysis
July 9th 2025

Measuring Urinary Antibiotic Levels May Indicate Depression Risk in Adolescents

Jessica Walters
Here's to a Psychedelic Revolution
April 9th 2022

Here's to a Psychedelic Revolution

Amir Inamdar MBBS, DNB (Psych), MFPM
History, Physiology, and Pharmacology of Incretins
July 2nd 2025

History, Physiology, and Pharmacology of Incretins

Roger S. McIntyre, MD, FRCPC
Blue Light, Depression, and Bipolar Disorder
August 4th 2021

Blue Light, Depression, and Bipolar Disorder

Chris Aiken, MD Kellie Newsome, PMH-NP
psychedelic
July 1st 2025

Positive Results From the Phase 2b Study of BPL-003 in Patients With Treatment-Resistant Depression

Leah Kuntz
psilocybin
June 23rd 2025

COMP360 Psilocybin for Treatment-Resistant Depression: Positive Phase 3 Efficacy Data

Leah Kuntz
© 2025 MJH Life Sciences

All rights reserved.